within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01ED05_Lorlatinib;

model Lorlatinib
  extends Pharmacolibrary.Drugs.ATC.L.L01ED05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01ED05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lorlatinib is a third-generation, reversible, macrocyclic tyrosine kinase inhibitor targeting anaplastic lymphoma kinase (ALK) and ROS1, approved for use in non-small cell lung cancer (NSCLC) patients with ALK-positive tumors, particularly after resistance to earlier-generation ALK inhibitors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with ALK-positive advanced NSCLC after oral administration under fasted conditions.</p><h4>References</h4><ol><li><p>Syed, YY (2019). Lorlatinib: First Global Approval. <i>Drugs</i> 79(1) 93–98. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-1041-0&quot;>10.1007/s40265-018-1041-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30604291/&quot;>https://pubmed.ncbi.nlm.nih.gov/30604291</a></p></li><li><p>Li, W, et al., &amp; Schinkel, AH (2019). Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</i> 136 120–130. DOI:<a href=&quot;https://doi.org/10.1016/j.ejpb.2019.01.016&quot;>10.1016/j.ejpb.2019.01.016</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30660696/&quot;>https://pubmed.ncbi.nlm.nih.gov/30660696</a></p></li><li><p>Patel, M, et al., &amp; Pithavala, YK (2020). The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. <i>Investigational new drugs</i> 38(1) 131–139. DOI:<a href=&quot;https://doi.org/10.1007/s10637-019-00872-7&quot;>10.1007/s10637-019-00872-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31728714/&quot;>https://pubmed.ncbi.nlm.nih.gov/31728714</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lorlatinib;
